Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

ADMISSION OF CONSIDERATION SHARES 28-02-2023, 21:28

JDE Peet’s recognised for Diversity Excellence with 2025 Catalyst Award 12-12-2024, 22:30